MondayAug 10, 2026 2:43 pm

QualityStocksNewsBreaks – Forward Industries Inc. (NASDAQ: FWDI) Expands Solana Holdings and Institutional Capital Access

Forward Industries (NASDAQ: FWDI) expanded its Solana treasury by more than 500,000 SOL during fiscal Q3 2026 at an average purchase price of approximately $79 per SOL, bringing its holdings to 7.55 million SOL as of June 30. The company also sold 93,642 shares through its at-the-market offering while reporting 36% annualized SOL-per-share growth, which it says demonstrates its ability to raise capital in an accretive manner. Following inclusion in the Russell 2000 and Russell 3000 indexes, Forward says it has additional access to institutional capital, while its proprietary fwdSOL staking token provides another source of liquidity. To view the full…

Continue Reading

MondayAug 10, 2026 10:50 am

QualityStocksNewsBreaks – AZIO AI Holdings, Inc. (NASDAQ: AZIO) Featured in AINewsWire Editorial on AI Power, Infrastructure Demand

AZIO AI Holdings (NASDAQ: AZIO) is featured in an AINewsWire editorial titled “As AI Races Ahead, the Real Battle Is Over Power and Infrastructure,” examining how accelerating artificial intelligence adoption is driving demand for the physical infrastructure required to support AI computing. The editorial highlights AZIO AI integrated infrastructure strategy, including its planned 500-megawatt Texas AI data-center campus, Master Services Agreement with AT&T for enterprise fiber connectivity and power purchase and AI infrastructure hosting agreement with Power Champion Investment Limited. The editorial also highlights AZIO AI recently announced letter of intent with Power Champion for the proposed acquisition of 128…

Continue Reading

MondayAug 10, 2026 9:30 am

QualityStocksNewsBreaks – MAX Power Mining Corp. (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) Secures $10 Million Strategic Private Placement With Eric Sprott

This article has been disseminated on behalf of MAX Power Mining and may include paid advertising. MAX Power Mining (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) announced a strategic non-brokered private placement with Eric Sprott for gross proceeds of $10 million. The financing consists of 4 million units priced at $2.50 each, to be subscribed for by 2176423 Ontario Ltd., a corporation beneficially owned by Sprott. Each unit includes one common share and one warrant exercisable at $3.25 for 24 months. Closing is anticipated on or about Aug. 17, 2026, subject to customary conditions, including Canadian Securities Exchange approval. MAX Power…

Continue Reading

MondayAug 10, 2026 9:10 am

QualityStocksNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Receives FDA Clearance to Advance Lucid-MS into Phase 2

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that the U.S. Food and Drug Administration has approved its Investigational New Drug (“IND”) application for Lucid-MS (Lucid-21-302), clearing the company to advance the patented, first-in-class multiple sclerosis candidate into Phase 2 clinical development. The planned randomized, double-blind, placebo-controlled study will evaluate efficacy, safety and tolerability in people with MS using clinical and radiological measures. Trial start-up activities, including site selection, are underway, with patient enrollment and drug administration expected to begin as quickly as possible. Lucid-MS…

Continue Reading

FridayAug 07, 2026 2:55 pm

QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Closer to Regulatory and Commercial Milestones

Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC hydrogel-based cartilage regeneration technology toward key clinical, regulatory and commercial milestones amid growing interest in regenerative orthopedic solutions. GelrinC is an off-the-shelf, cell-free implant designed for a streamlined, single-step procedure that supports cartilage regeneration without the cell harvesting and laboratory processing required by some alternative approaches. Regentis is continuing enrollment in its U.S. clinical study, preparing for a potential FDA Premarket Approval submission, expanding commercialization efforts in Europe following CE Mark approval, and optimizing manufacturing for scalability and consistency. To view the full article, visit https://ibn.fm/mVCsB About Regentis Biomaterials Ltd. Regentis Biomaterials is a…

Continue Reading

FridayAug 07, 2026 2:12 pm

QualityStocksNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Two-Pronged Approach to Neurological Health

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies, is developing a two-pronged strategy addressing neurological health through its investigational multiple sclerosis therapy Lucid-MS and its proprietary dietary supplement unbuzzd. Lucid-MS is designed to target PAD2, an enzyme associated with myelin degradation, with the goal of protecting and potentially restoring the myelin sheath rather than primarily modulating the immune system. The company submitted an IND application to the FDA for a Phase 2 trial and is supporting development through an imaging collaboration…

Continue Reading

FridayAug 07, 2026 1:04 pm

QualityStocksNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Builds Strategic Position in Antibody Therapeutics Market

VERAXA Biotech (NASDAQ: VRXA) is developing next-generation antibody therapeutics across antibody-drug conjugates (“ADCs”) and T-cell engagers (“TCEs”), two areas that continue to attract significant pharmaceutical investment. A recent article highlights major transactions to illustrate how differentiated antibody-engineering platforms can attract substantial financial commitments even before clinical development reaches advanced stages. VERAXA’s proprietary BiTAC platform supports a pipeline that includes bispecific ADCs, T-cell engagers and engineered antibody formats, potentially creating opportunities for future platform partnerships, licensing agreements or asset-level transactions. To view the full article, visit https://ibn.fm/sMjlp About VERAXA Biotech AG VERAXA is building a premier engine for the discovery and development of…

Continue Reading

FridayAug 07, 2026 10:37 am

QualityStocksNewsBreaks – AZIO AI Holdings, Inc. (NASDAQ: AZIO) Featured in AINewsWire Editorial on AI Compute Infrastructure 

AZIO AI Holdings (NASDAQ: AZIO) announced its inclusion in an AINewsWire ("AINW") editorial examining the growing shortage of AI compute infrastructure and its implications for the next phase of artificial intelligence adoption. The editorial, titled "The Compute Shortage Threatening AI's Next Growth Phase," highlights industry forecasts calling for an estimated $6.7 trillion in AI-related data center investment by 2030 and discusses AZIO's strategy to address increasing demand for AI compute capacity. The editorial also spotlights AZIO's recently announced agreement with Power Champion Investment Limited for the purchase of up to 128 NVIDIA(TM) B300 GPU systems, positioning the company as an emerging provider of AI infrastructure. The editorial notes that the…

Continue Reading

FridayAug 07, 2026 9:20 am

QualityStocksNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Reports 57% Increase in Fiscal First-Quarter Net Income

Earth Science Tech (OTC: ETST) reported fiscal first-quarter 2027 results highlighted by a 57% year-over-year increase in net income to $715,697 on revenue of $9.0 million, up 3% from the prior-year period. Gross profit rose to $6.3 million, operating cash flow more than doubled to $707,131 and total assets increased to $10.4 million. Diluted earnings per share improved to $0.003 from $0.001, while the company repurchased and retired more than 3.7 million common shares during the quarter without adding debt. The company said all key operating subsidiaries remained profitable as it continued expanding the licensing footprint of its compounding pharmacy…

Continue Reading

FridayAug 07, 2026 9:00 am

QualityStocksNewsBreaks – Wrap Technologies, Inc. (NASDAQ: WRAP) Launches WrapTactics LMS, Completing WrapShield Training Foundation

Wrap Technologies (NASDAQ: WRAP) announced the commercial launch of WrapTactics(TM) Learning Management System ("LMS"), completing the training foundation of its WrapShield(TM) six-tier human-centered response architecture. The platform provides digital learning, certification management, immersive virtual reality training, compliance reporting and mobile learning to support deployment of the company's non-lethal response technologies, including BolaWrap(R) 150. The launch follows the U.S. Bureau of Alcohol, Tobacco, Firearms and Explosives' 2026 classification of BolaWrap 150 as an instrument of restraint rather than a firearm or weapon, a determination the company said expands procurement opportunities beyond traditional law enforcement markets. Wrap said WrapTactics is designed to create…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered